Stephens Inc’s Novavax NVAX Stock Holding History

Stephens Inc’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,013	Closed	-$23K	–	819
2017 Q2	$23K	Hold	1,013	–	–	﹤0.01%	856
2017 Q1	$26K	Buy	1,013 +250	+33%	+$6.88K	﹤0.01%	828
2016 Q4	$19K	Buy	+763	New	+$22.3K	﹤0.01%	782

Other funds holding NVAX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stephens Inc's NVAX Position: Q3 2017 in Review

Stephens Inc sold out of Novavax (NVAX) in Q3 2017, closing a stake of 1,013 shares — an estimated $23K sold.

Stephens Inc first reported a position in NVAX in Q4 2016 and held it in 3 quarters. The position peaked at $26K in Q1 2017. 128 funds tracked by Wall St. Rank hold NVAX as of Q3 2017.

Stephens Inc reported no remaining Novavax position as of Q3 2017 after selling out during the quarter.
Stephens Inc sold 1,013 Novavax shares in Q3 2017, an estimated $23K.
Stephens Inc first reported a position in Novavax in Q4 2016 and held it in 3 quarters.
Stephens Inc's Novavax position peaked at $26K in Q1 2017.
128 funds tracked by Wall St. Rank held Novavax as of Q3 2017.

Based on Stephens Inc's 13F filing for Q3 2017, filed 8 Nov 2017.